{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T05:11:20Z","timestamp":1697260280605},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s00115-023-01544-x","type":"journal-article","created":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T10:01:46Z","timestamp":1696586506000},"page":"904-912","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapie\u00a0\u2013 Quo vadis Neurodegeneration?","Treatment\u2014Quo vadis neurodegeneration?"],"prefix":"10.1007","volume":"94","author":[{"given":"Jonathan","family":"V\u00f6glein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Levin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00fcnter","family":"H\u00f6glinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,10,6]]},"reference":[{"issue":"6","key":"1544_CR1","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1111\/ene.14800","volume":"28","author":"J V\u00f6glein","year":"2022","unstructured":"V\u00f6glein\u00a0J, Kostova\u00a0I, Arzberger\u00a0T et\u00a0al (2022) First symptom guides diagnosis and prognosis in neurodegenerative diseases\u2014A retrospective study of autopsy proven cases. Eur J Neurol 28(6):1801\u20131811","journal-title":"Eur J Neurol"},{"issue":"12","key":"1544_CR2","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1002\/alz.12362","volume":"17","author":"KB Rajan","year":"2021","unstructured":"Rajan\u00a0KB, Weuve\u00a0J, Barnes\u00a0LL et\u00a0al (2021) Population estimate of people with clinical Alzheimer\u2019s disease and mild cognitive impairment in the United States (2020\u20132060). Alzheimers Dement 17(12):1966\u20131975","journal-title":"Alzheimers Dement"},{"issue":"4","key":"1544_CR3","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1002\/alz.12638","volume":"18","author":"Alzheimer\u2019s Association","year":"2022","unstructured":"Alzheimer\u2019s Association (2022) 2022 Alzheimer\u2019s disease facts and figures. Alzheimers Dement 18(4):700\u2013789","journal-title":"Alzheimers Dement"},{"issue":"Suppl","key":"1544_CR4","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1038\/nm1066","volume":"10","author":"A Ross","year":"2004","unstructured":"Ross\u00a0A, Poirier\u00a0MA (2004) Protein aggregation and neurodegenerative diseases. Nat Med 10(Suppl):S10\u2013S17","journal-title":"Nat Med"},{"issue":"Suppl 1","key":"1544_CR5","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1016\/j.parkreldis.2017.07.033","volume":"46","author":"DW Dickson","year":"2018","unstructured":"Dickson\u00a0DW (2018) Neuropathology of Parkinson disease. Parkinsonism Relat Disord 46(Suppl 1):S30\u2013S33","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"1544_CR6","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1056\/NEJMra1311488","volume":"372","author":"A Fanciulli","year":"2015","unstructured":"Fanciulli\u00a0A, Wenning\u00a0GK (2015) Multiple-system atrophy. N\u00a0Engl J Med 372(3):249\u2013263","journal-title":"N Engl J Med"},{"key":"1544_CR7","first-page":"146","volume":"64","author":"A Alzheimer","year":"1907","unstructured":"Alzheimer\u00a0A (1907) \u00dcber eine eigenartige Erkrankung der Hirnrinde. Allg Z Psychiatr Psych Gerichtl Med 64:146\u2013148","journal-title":"Allg Z Psychiatr Psych Gerichtl Med"},{"issue":"6","key":"1544_CR8","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/mds.26987","volume":"32","author":"GU H\u00f6glinger","year":"2017","unstructured":"H\u00f6glinger\u00a0GU, Respondek\u00a0G, Stamelou\u00a0M et\u00a0al (2017) Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord 32(6):853\u2013864","journal-title":"Mov Disord"},{"issue":"1","key":"1544_CR9","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00401-008-0460-5","volume":"117","author":"I Mackenzie","year":"2009","unstructured":"Mackenzie\u00a0I, Neumann\u00a0M, Bigio\u00a0EH et\u00a0al (2009) Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. Acta Neuropathol 117(1):15\u201318","journal-title":"Acta Neuropathol"},{"issue":"12","key":"1544_CR10","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1002\/alz.12624","volume":"18","author":"J Levin","year":"2023","unstructured":"Levin\u00a0J, V\u00f6glein\u00a0J, Quiroz\u00a0Y et\u00a0al (2023) Testing the amyloid cascade hypothesis: prevention trials in autosomal dominant Alzheimer disease. Alzheimers Dement 18(12):2687\u20132698","journal-title":"Alzheimers Dement"},{"key":"1544_CR11","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00608-021-00870-0","volume":"56","author":"A Eisenk\u00f6lbl","year":"2021","unstructured":"Eisenk\u00f6lbl\u00a0A (2021) Neue Therapiem\u00f6glichkeiten der spinalen Muskelatrophie. Paediatr Paedolog 56:59\u201366","journal-title":"Paediatr Paedolog"},{"issue":"12","key":"1544_CR12","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1007\/s00115-021-01218-6","volume":"92","author":"J Levin","year":"2021","unstructured":"Levin\u00a0J, Oertel\u00a0W (2021) Proteinbezogene Therapien neurodegenerativer Erkrankungen. Nervenarzt 92(12):1217\u20131218","journal-title":"Nervenarzt"},{"issue":"3","key":"1544_CR13","first-page":"426","volume":"10","author":"L Iaccarino","year":"2023","unstructured":"Iaccarino\u00a0L, Burnham\u00a0SC, Dell\u2019Agnello\u00a0G et\u00a0al (2023) Diagnostic biomarkers of amyloid and tau pathology in Alzheimer\u2019s disease: an overview of tests for clinical practice in the United States and Europe. J\u00a0Prev Alzheimers Dis 10(3):426\u2013442","journal-title":"J Prev Alzheimers Dis"},{"issue":"11","key":"1544_CR14","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1001\/jamaneurol.2021.3180","volume":"78","author":"S Janelidze","year":"2021","unstructured":"Janelidze\u00a0S, Teunissen\u00a0CE, Zetterberg\u00a0H et al (2021) Head-to-head comparison of 8 plasma amyloid\u2011\u03b2 42\/40 assays in Alzheimer disease. JAMA Neurol 78(11):1375\u20131382","journal-title":"JAMA Neurol"},{"issue":"11","key":"1544_CR15","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.1093\/brain\/awaa276","volume":"143","author":"DN Soleimani-Meigooni","year":"2020","unstructured":"Soleimani-Meigooni\u00a0DN, Iaccarino\u00a0L, La Joie\u00a0R et al (2020) 18F-flortaucipir PET to autopsy comparisons in Alzheimer\u2019s disease and other neurodegenerative diseases. Brain 143(11):3477\u20133494","journal-title":"Brain"},{"key":"1544_CR16","doi-asserted-by":"crossref","unstructured":"Horie K, Salvad\u00f3 G, Barth\u00e9lemy NR et al (2023) CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer\u2019s disease. Nat Med 29(8):1954-1963","DOI":"10.1038\/s41591-023-02443-z"},{"issue":"12","key":"1544_CR17","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1038\/s41591-022-02075-9","volume":"28","author":"K Horie","year":"2022","unstructured":"Horie\u00a0K, Barthelemy\u00a0NR, Spina\u00a0S et al (2022) CSF tau microtubule-binding region identifies pathologcial changes in primary tauopathies. Nat Med 28(12):2547\u20132554","journal-title":"Nat Med"},{"issue":"4","key":"1544_CR18","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1093\/brain\/awac333","volume":"146","author":"S Janelidze","year":"2023","unstructured":"Janelidze\u00a0S, Bali\u00a0D, Ashton\u00a0NJ et al (2023) Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer\u2019s disease. Brain 146(4):1592\u20131601","journal-title":"Brain"},{"issue":"5","key":"1544_CR19","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S1474-4422(23)00109-6","volume":"22","author":"A Siderowf","year":"2023","unstructured":"Siderowf\u00a0A, Concha-Marambio\u00a0L, Lafontant\u00a0DE et al (2023) Assessment of heterogeneity among participants in the Parkinson\u2019s progression markers initiative cohort using \u03b1\u2011synuclein seed amplification: a\u00a0cross-sectional study. Lancet Neurol 22(5):407\u2013417","journal-title":"Lancet Neurol"},{"issue":"4","key":"1544_CR20","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1002\/ana.26453","volume":"92","author":"MR Arnold","year":"2022","unstructured":"Arnold\u00a0MR, Coughlin\u00a0DG, Brumbach\u00a0BH et al (2022) \u03b1\u2011Synuclein seed amplification in CSF and brain from patients with different brain distributions of pathological \u03b1\u2011Synuclein in the context of co-pathology and non-LBD diagnoses. Ann Neurol 92(4):650\u2013662","journal-title":"Ann Neurol"},{"issue":"5","key":"1544_CR21","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1002\/mds.28984","volume":"37","author":"OM Alzghool","year":"2022","unstructured":"Alzghool\u00a0OM, Van Dongen\u00a0G, Van de Giessen\u00a0E et al (2022) \u03b1\u2011Synuclein radiotracer development and in vivo imaging: recent advancements and new perspectives. Mov Disord 37(5):936\u2013948","journal-title":"Mov Disord"},{"issue":"6","key":"1544_CR22","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1038\/s41591-023-02358-9","volume":"29","author":"A Okuzumi","year":"2023","unstructured":"Okuzumi\u00a0A, Hatano\u00a0T, Matsumoto\u00a0G et al (2023) Propagative \u03b1\u2011synuclein seeds as serum biomarkers for synucleinopathies. Nat Med 29(6):1448\u20131455","journal-title":"Nat Med"},{"issue":"9","key":"1544_CR23","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.1093\/brain\/awac115","volume":"145","author":"A Kluge","year":"2022","unstructured":"Kluge\u00a0A, Bunk\u00a0J, Schaeffer\u00a0E et al (2022) Detection of neuron-derived pathological \u03b1\u2011synuclein in blood. Brain 145(9):3058\u20133071","journal-title":"Brain"},{"issue":"4","key":"1544_CR24","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/S1474-4422(22)00027-8","volume":"21","author":"E Morenas-Rodriguez","year":"2022","unstructured":"Morenas-Rodriguez\u00a0E, Li\u00a0Y, Nuscher\u00a0B et al (2022) Soluble TREM2 in CSF and ist association with other biomarkers and cognition in autosomal-dominant Alzheimer\u2019s disease: a\u00a0longitudinal observational study. Lancet Neurol 21(4):329\u2013341","journal-title":"Lancet Neurol"},{"issue":"7","key":"1544_CR25","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1002\/alz.12879","volume":"19","author":"P Chatterjee","year":"2023","unstructured":"Chatterjee\u00a0P, Vermunt\u00a0L, Gordon\u00a0BA et al (2023) Plasma glial fibrillary acidic protein in autosomal dominant Alzheimer\u2019s disease: associations with A\u03b2-PET, neurodegeneration, and cognition. Alzheimers Dement 19(7):2790\u20132804","journal-title":"Alzheimers Dement"},{"issue":"648","key":"1544_CR26","doi-asserted-by":"publisher","first-page":"eabj2658","DOI":"10.1126\/scitranslmed.abj2658","volume":"14","author":"D Jennings","year":"2022","unstructured":"Jennings\u00a0D, Huntwork-Rodriguez\u00a0S, Henry\u00a0AG et al (2022) Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson\u2019s disease. Sci Transl Med 14(648):eabj2658","journal-title":"Sci Transl Med"},{"issue":"1","key":"1544_CR27","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/S1474-4422(20)30412-9","volume":"20","author":"A Serrano-Pozo","year":"2021","unstructured":"Serrano-Pozo\u00a0A, Das\u00a0S, Hyman\u00a0BT et al (2021) APOE and Alzheimer\u2019s disease: advances in genetics, pathophysiology, and therapeutic approaches. Lancet Neurol 20(1):68\u201380","journal-title":"Lancet Neurol"},{"issue":"7","key":"1544_CR28","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/nrg.2016.27","volume":"17","author":"N Chatterjee","year":"2016","unstructured":"Chatterjee\u00a0N, Shi\u00a0J, Garcia-Closas\u00a0M (2016) Developing and evaluating polygenic risk prediction models for stratified disease prevention. Nat Rev Genet 17(7):392\u2013406","journal-title":"Nat Rev Genet"},{"issue":"5","key":"1544_CR29","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1002\/mds.24954","volume":"27","author":"A Siderowf","year":"2012","unstructured":"Siderowf\u00a0A, Lang\u00a0AE (2012) Pre-motor Parkinson\u2019s disease: concepts and definitons. Mov Disord 27(5):608\u2013616","journal-title":"Mov Disord"},{"issue":"5","key":"1544_CR30","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1093\/brain\/awz050","volume":"142","author":"J V\u00f6glein","year":"2019","unstructured":"V\u00f6glein\u00a0J, Paumier\u00a0K, Jucker\u00a0M et\u00a0al (2019) Clinical, pathophysiological and genetic features of motor symptoms in autosomal dominant Alzheimer\u2019s disease. Brain 142(5):1429\u20131440","journal-title":"Brain"},{"issue":"2","key":"1544_CR31","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1002\/alz.12684","volume":"19","author":"J V\u00f6glein","year":"2023","unstructured":"V\u00f6glein\u00a0J, Franzmeier\u00a0N, Morris\u00a0JC et\u00a0al (2023) Pattern and implications of neurological examination findings in autosomal dominant Alzheimer disease. Alzheimers Dement 19(2):632\u2013645","journal-title":"Alzheimers Dement"},{"issue":"4","key":"1544_CR32","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.cell.2022.12.032","volume":"186","author":"DM Wilson 3rd","year":"2022","unstructured":"Wilson\u00a0DM 3rd, Cookson\u00a0MR, Van Den Bosch\u00a0L et\u00a0al (2022) Hallmarks of neurodegenerative diseases. Cell 186(4):693\u2013714","journal-title":"Cell"},{"issue":"1","key":"1544_CR33","first-page":"25","volume":"10","author":"C Fang","year":"2023","unstructured":"Fang\u00a0C, Hernandez\u00a0P, Liow\u00a0K et\u00a0al (2023) Buntanetap, a\u00a0novel translational inhibitor of multiple neurotoxic proteins, proves to be safe and promising in both Alzheimer\u2019s and Parkinson\u2019s patients. J\u00a0Prev Alzheimers Dis 10(1):25\u201333","journal-title":"J Prev Alzheimers Dis"},{"issue":"5440","key":"1544_CR34","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1126\/science.286.5440.735","volume":"286","author":"R Vassar","year":"1999","unstructured":"Vassar\u00a0R, Bennett\u00a0BD, Babu-Kahn\u00a0S et al (1999) Beta-secretase cleavage of Alzheimer\u2019s amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286(5440):735\u2013741","journal-title":"Science"},{"issue":"1","key":"1544_CR35","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH Van Dyck","year":"2023","unstructured":"Van Dyck\u00a0CH, Swanson\u00a0CJ, Aisen\u00a0P et\u00a0al (2023) Lecanemab in early Alzheimer\u2019s disease. N\u00a0Engl J Med 388(1):9\u201321","journal-title":"N Engl J Med"},{"key":"1544_CR36","first-page":"e2313239","volume":"17","author":"JR Sims","year":"2023","unstructured":"Sims\u00a0JR, Zimmer\u00a0JA, Evans\u00a0CD et al (2023) Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 17:e2313239","journal-title":"JAMA"},{"key":"1544_CR37","unstructured":"https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-converts-novel-alzheimers-disease-treatment-traditional-approval"},{"issue":"2","key":"1544_CR38","first-page":"197","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein\u00a0S, Aisen\u00a0PS et\u00a0al (2022) Two randomized phase\u00a03 studies of aducanumab in early Alzheimer\u2019s disease. J\u00a0Prev Alzheimers Dis 9(2):197\u2013210","journal-title":"J Prev Alzheimers Dis"},{"key":"1544_CR39","unstructured":"https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-grants-accelerated-approval-alzheimers-drug"},{"issue":"5","key":"1544_CR40","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1056\/NEJMoa2202867","volume":"387","author":"G Pagano","year":"2022","unstructured":"Pagano\u00a0G, Taylor\u00a0KI, Anzures-Cabrera\u00a0J et al (2022) Trial of prasinezumab in early-stage Parkinson\u2019s disease. N\u00a0Engl J Med 387(5):421\u2013432","journal-title":"N Engl J Med"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-023-01544-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00115-023-01544-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-023-01544-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T08:04:09Z","timestamp":1697184249000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00115-023-01544-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["1544"],"URL":"https:\/\/doi.org\/10.1007\/s00115-023-01544-x","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"9 August 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"J.\u00a0V\u00f6glein hat ein Beratungshonorar von Eisai erhalten. Ihm wurden Kongresskosten von Biogen und der Alzheimer\u2019s Association und Reise- und \u00dcbernachtungskosten von der \u00d6sterreichischen Alzheimer Gesellschaft erstattet, au\u00dferhalb der eingereichten Arbeit. J.\u00a0Levin berichtet Vortragshonorare von Bayer Vital, Biogen, Eisai, TEVA, Zambon and Roche, Beratungshonorare von Axon Neuroscience, Eisai and Biogen, Autorenhonorare von Thieme (Medizinverlag) und W. Kohlhammer GmbH (Medizinverlag) und ist Erfinder in einem von der LMU M\u00fcnchen angemeldeten Patent \u201cOral Phenylbutyrate for Treatment of Human 4-Repeat Tauopathies\u201d (EP 23 156 122.6). Dar\u00fcber hinaus meldet er eine Verg\u00fctung f\u00fcr seine T\u00e4tigkeit als Chief Medical Officer der MODAG GmbH, ist Beg\u00fcnstigter des Phantomaktienprogramms der MODAG GmbH und Erfinder in einem von der MODAG GmbH angemeldeten Patent \u201ePharmaceutical Composition and Methods of Use\u201c (EP 22 159 408.8), au\u00dferhalb der eingereichten Arbeit. G.\u00a0H\u00f6glinger gibt Beratert\u00e4tigkeiten f\u00fcr Abbvie, Alzprotect, Amylyx, Aprineua, Asceneuron, Bayer, Bial, Biogen, Biohaven, Epidarex, Ferrer, Kyowa Kirin, Lundbeck, Novartis, Retrotope, Roche, Sanofi, Servier, Takeda, Teva und UCB an. Er erhielt Honorare f\u00fcr wissenschaftliche Pr\u00e4sentationen von Abbvie, Bayer, Bial, Biogen, Bristol Myers Squibb, Kyowa Kirin, Pfizer, Roche, Teva, UCB und Zambon, au\u00dferhalb der eingereichten Arbeit.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}